Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Neonatal morphine is commonly administered in the Neonatal Intensive Care Unit (NICU) to manage pain. However, its long-term effects on neurodevelopment of pain pathways, remain a significant concern. The midbrain is a core region that plays a central role in pain processing and opioid-mediated analgesia. Here, we performed single-cell RNA sequencing to study gene expression in 107,427 midbrain single cells from adolescent mice neonatally exposed to either saline, morphine, or morphine with the probiotic (). We found broad alterations in transcriptomics within neurons, astrocytes, oligodendrocytes, and microglial cells. Analysis of differentially regulated genes revealed down regulation of HOX genes and upregulation of pathways related to neurotransmitter signaling and pain in adolescence that were neonatally treated with morphine. Interestingly, neonatal probiotic supplementation mitigated these morphine-induced alterations on the transcriptome. This study presents the first single-cell RNA sequencing dataset of the adolescent midbrain following neonatal morphine exposure and probiotic intervention. These findings offer new insights into the neurodevelopmental impact of early opioid exposure and highlight the therapeutic potential of microbiome-targeted interventions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12157604PMC
http://dx.doi.org/10.1101/2025.05.30.657034DOI Listing

Publication Analysis

Top Keywords

neonatal morphine
8
single-cell rna
8
rna sequencing
8
neonatal
5
pain
5
morphine
5
single-cell transcriptomics
4
transcriptomics reveals
4
probiotic
4
reveals probiotic
4

Similar Publications

Design of a Long-Acting Morphine Prodrug for Safe Opioid Delivery.

ChemMedChem

August 2025

Department of Pharmaceutical Sciences, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA, 95211, USA.

Effective opioid management in neonatal abstinence syndrome (NAS) and opioid use disorder (OUD) requires maintaining low, stable plasma opioid levels to prevent withdrawal without central side effects. Current treatments rely on frequent opioid dosing, such as oral morphine every few hours for up to 3 weeks in NAS, leading to plasma level fluctuations and increased risk of toxicity or withdrawal. Herein, the design and characterization of AG10-L-E2-morphine, a prodrug that forms a zwitterionic subcutaneous depot for sustained morphine release is reported.

View Article and Find Full Text PDF

Nonpharmacologic management is the first-line therapy for infants experiencing neonatal opioid withdrawal syndrome (NOWS) and/or neonatal abstinence syndrome (NAS). Currently, the most prescribed first-line pharmacologic agent is an opioid, most often morphine, but methadone and buprenorphine are preferred by some providers. For some infants, an opioid, along with maximized nonpharmacologic strategies, does not provide adequate symptom relief and a second-line agent is needed.

View Article and Find Full Text PDF

Background And Objectives: Identifying neonates at risk for neonatal opioid withdrawal syndrome (NOWS) is important to ensure adequate monitoring and treatment. We sought to evaluate 3 screening modalities-maternal history and physical (H&P), maternal urine drug screening (MUDS), and neonatal urine drug screening (NUDS)-in the identification of neonates at risk for NOWS.

Methods: Retrospective chart review was conducted for neonates with documented neonatal Finnegan scores at the University of Maryland Medical Center in Baltimore, Maryland, from January 1, 2017, through January 1, 2022.

View Article and Find Full Text PDF

Pain management in the first 1000 days of life is crucial for neurodevelopmental outcomes and the quality of life in extremely preterm newborns, who often undergo mechanical ventilation. The use of drugs like midazolam in neonatal care offers advantages such as sedation and muscle relaxation, but can also lead to potential adverse effects. Morphine, a common opioid analgesic, is used in neonatal care for its dual analgesic and sedative properties.

View Article and Find Full Text PDF

Evaluation of Therapeutic Opioids in Hair of Neonatal and Pediatric Patients.

Drug Test Anal

July 2025

Center for Forensic Hair Analysis, Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland.

Forensic hair analysis poses a valuable tool for assessing opioid exposure in children and neonates. However, reliable literature data on opioid concentrations in the hair of this population are mostly scarce, making the interpretation of such hair analysis results rather challenging. This noninterventional study aims to address this issue by investigating 118 hair samples of pediatric patients (median age: 50 days) from the University Children's Hospital Zurich.

View Article and Find Full Text PDF